source
- Entrada Therapeutics' next-gen Duchenne drug fails early trial, raising competitive concernsEntrada Therapeutics reported that its next-generation exon-skipping therapy for Duchenne muscular dystrophy did not meet efficacy endpoints in an early-stage study. The trial, which evaluated the…
- FDA staff cuts leave agency scrambling to rebuild workforce after 3,500 layoffsThe Food and Drug Administration dismissed roughly 3,500 employees last year as part of a health‑policy push to reduce what officials called bureaucratic bloat. The mass layoffs have left the agenc…